Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

William Sandeson’s appeal of murder conviction dismissed by Nova Scotia court

December 13, 2025

Decade-long analysis looks at domestic homicide rates in Atlantic provinces

December 13, 2025

Princeton, B.C. under flood watch as Tulameen, Similkameen rise amid atmospheric river

December 13, 2025

Kelowna boasts highest vacancy rate of any Canadian metropolitan area

December 12, 2025

Ottawa, Alberta agreed to extend $15-a-day child-care fees to 2027

December 12, 2025
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of NYCB
Press Release

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of NYCB

By News RoomMarch 19, 20244 Mins Read
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of NYCB
Share
Facebook Twitter LinkedIn Pinterest Email
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of NYCB

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against New York Community Bancorp, Inc. (“NYCB” or the “Company”) (NYSE: NYCB) and reminds investors of the April 8, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In NYCB To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000 investing in NYCB stock or options between March 1, 2023 and February 5, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/NYCB.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Signature Bank acquisition would not be immediately accretive to New York Community Bancorp because it caused New York Community Bancorp to be required to comply with materially enhanced prudential standards, including, among other things, risk-based and leverage capital requirements, and liquidity standards, and required that New York Community Bancorp build capital, reinforce its balance sheet and strengthen its risk management processes; (ii) New York Community Bancorp failed to comply with the materially enhanced prudential standards; (iii) New York Community Bancorp overstated the quality of its commercial office loan assets; (iv) New York Community Bancorp was experiencing higher net charge-offs and deterioration in its commercial office portfolio than represented; (v) New York Community Bancorp was reasonably likely to incur higher loan losses because it was experiencing higher net charge-offs and deterioration in its commercial office portfolio; (vi) New York Community Bancorp was reasonably likely to be forced to increase its allowance for credit losses due to its status as Category IV bank; (vii) New York Community Bancorp’s loan loss provisions were understated so it overstated quarterly earnings and/or understated quarterly losses; and (viii) New York Community Bancorp failed to have adequate internal risk or disclosure controls and procedures.

On January 31, 2024, New York Community Bancorp disclosed that it had recorded a $552 million provision for loan losses, up significantly from the $62 million reported just one quarter earlier, and that as a result, New York Community Bancorp had incurred a 4Q23 loss of $252 million, or $0.36 per share, down significantly from a profit of $0.27 per share Wall Street consensus estimate. New York Community Bancorp also disclosed it would cut its quarterly dividend from $0.17 to $0.05 per share. On this news, the price of New York Community Bancorp stock fell nearly 38%.

Then, on February 5, 2024, Bloomberg reported, citing “people with direct knowledge of the matter,” that it had been “mounting pressure from a top US watchdog” that “led to” New York Community Bancorp’s “surprise decision to slash its dividend and stockpile cash in case commercial real estate loans [went] bad.” According to the Bloomberg article, “[t]he drastic financial moves . . . followed behind-the-scenes conversations with officials from the Office of the Comptroller of the Currency, the people said, asking not to be identified describing the confidential discussions.” On this news, the price of New York Community Bancorp stock fell more than 22%.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding NYCB’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8cccb513-acce-46c7-a85f-f8dd598c2689

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Alameda Health System reminds community: Apply for Medi-Cal before December 31, 2025

GeeFi Announces Major Community Giveaway to Celebrate Presale Success

Billor for Brokers Strengthens Specialized Freight Capacity with Live Bee Hauling Operations

GeeFi (GEE) Launches High-Reward Referral Program to Accelerate Community Growth

NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways

Park Dental Partners Rings the Closing Bell on the Nasdaq in New York

Alpine Bank celebrates the enduring legacy of Founder J. Robert “Bob” Young

Over-the-Counter (OTC) Commodity Trading Platforms Market Report 2025

Editors Picks

Decade-long analysis looks at domestic homicide rates in Atlantic provinces

December 13, 2025

Princeton, B.C. under flood watch as Tulameen, Similkameen rise amid atmospheric river

December 13, 2025

Kelowna boasts highest vacancy rate of any Canadian metropolitan area

December 12, 2025

Ottawa, Alberta agreed to extend $15-a-day child-care fees to 2027

December 12, 2025

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Rare footage shows dolphins helping orcas hunt off B.C. coast

December 12, 2025

COMMENTARY: Possible relocation of Wildwood Golf Course is concerning residents

December 12, 2025

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

December 12, 2025
Facebook X (Twitter) Pinterest TikTok Instagram
© 2025 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version